DAX22.497 +0,3%ESt505.160 ±0,0%Top 10 Crypto12,19 -3,2%Dow40.753 +0,2%Nas17.711 +1,5%Bitcoin85.414 ±0,0%Euro1,1324 +0,3%Öl62,48 +1,0%Gold3.250 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Microsoft 870747 Amazon 906866 Apple 865985 Rheinmetall 703000 Tesla A1CX3T Meta Platforms (ex Facebook) A1JWVX Palantir A2QA4J Microstrategy 722713 Novo Nordisk A3EU6F RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Alphabet A (ex Google) A14Y6F BASF BASF11 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX vorbörslich marginal tiefer -- Asiens Börsen mehrheitlich in Grün -- Amazon verdient mehr als erwartet -- Apple, Airbus, Mercedes-Benz, BigBear.ai im Fokus
Top News
BASF-Chef steht Aktionären Rede und Antwort BASF-Chef steht Aktionären Rede und Antwort
Stocks in Action: Chipotle Mexican Grill, SPS Commerce Stocks in Action: Chipotle Mexican Grill, SPS Commerce
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
"600% Momentum-Strategie": Aktien hebeln und Gewinne maximieren - sichern Sie sich jetzt das Kennenlernangebot für nur 39 Euro (statt 69 Euro) im Monat!

Palatin Technologies Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
0,1722 EUR +0,0022 EUR +1,29 %
FSE
0,2199 USD +0,0329 USD +17,59 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.4,99 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DTUW

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6960775020

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPTN

Palatin Technologies Aktien News

DatumMeistgelesen
PR NewswirePalatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
PR NewswirePalatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
PR NewswirePalatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
PR NewswirePalatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
PR NewswirePalatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
PR NewswirePalatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
PR NewswirePalatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
PR NewswirePalatin Receives Notice of Non-Compliance from NYSE American
PR NewswirePalatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
PR NewswirePalatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
PR NewswirePalatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PR NewswirePalatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
PR NewswirePalatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
PR NewswirePalatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
PR NewswirePalatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
PR NewswirePalatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results
PR NewswirePalatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
PR NewswirePalatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
PR NewswirePalatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023
PR NewswirePalatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference
PR NewswirePalatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar
PR NewswirePalatin Technologies to Host Key Opinion Leader Webinar
PR NewswirePalatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference
PR NewswirePalatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma
PR NewswirePalatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results
PR NewswirePre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences
PR NewswireFrontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease
PR NewswirePalatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
PR NewswirePalatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
PR NewswirePalatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
PR NewswirePalatin Receives $4.7 Million of Non-Dilutive Funding
PR NewswireFrontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
PR NewswirePalatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
PR NewswirePalatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
PR NewswirePalatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
PR NewswirePalatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting
PR NewswireFirst Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial
PR NewswirePalatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results
PR NewswirePalatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
PR NewswirePalatin to Participate in Ladenburg Thalmann Healthcare Conference
Wer­bung

Palatin Technologies News

Palatin Technologies News: auf dieser Seite finden Sie alle Palatin Technologies News und Nachrichten zur Palatin Technologies Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Palatin Technologies News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Palatin Technologies News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.